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Epstein-Barr virus (EBV), which infects not only B cells but also T and natural killer (NK)
cells, is associated with a variety of lymphoid malignancies. Because EBV-associated
T and NK cell lymphomas are refractory and resistant to conventional chemotherapy,
there is a continuing need for new effective therapies. EBV-encoded “latent membrane
protein 1” (LMP1) is a major oncogene that activates nuclear factor kappa B (NF-κB),
c-Jun N-terminal kinase (JNK), and phosphatidylinositol 3-kinase signaling pathways,
thus promoting cell growth and inhibiting apoptosis. Recently, we screened a library
of small-molecule inhibitors and isolated heat shock protein 90 (Hsp90) inhibitors as
candidate suppressors of LMP1 expression. In this study, we evaluated the effects
of BIIB021, a synthetic Hsp90 inhibitor, against EBV-positive and -negative T and NK
lymphoma cell lines. BIIB021 decreased the expression of LMP1 and its downstream
signaling proteins, NF-κB, JNK, and Akt, in EBV-positive cell lines. Treatment with
BIIB021 suppressed proliferation in multiple cell lines, although there was no difference
between the EBV-positive and -negative lines. BIIB021 also induced apoptosis and
arrested the cell cycle at G1 or G2. Further, it down-regulated the protein levels of CDK1,
CDK2, and cyclin D3. Finally, we evaluated the in vivo effects of the drug; BIIB021
inhibited the growth of EBV-positive NK cell lymphomas in a murine xenograft model.
These results suggest that BIIB021 has suppressive effects against T and NK lymphoma
cells through the induction of apoptosis or a cell cycle arrest. Moreover, BIIB021 might
help to suppress EBV-positive T or NK cell lymphomas via the down-regulation of LMP1
expression.
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Introduction
Epstein-Barr virus (EBV), which was discovered in Burkitt lymphoma cells in 1964, was the first
human oncovirus to be described (Epstein et al., 1964). EBV infects B cells, and is associated with
several B malignancies, including Burkitt lymphoma, Hodgkin lymphoma, and post-transplant
lymphoproliferative disorders (Cohen, 2000; Kimura et al., 2013). However, EBV infects not only
B cells but also T and natural killer (NK) cells and is associated with a variety of T cell and NK cell
malignancies, including extranodal NK/T cell lymphoma nasal type (Chan et al., 2008b), hydroa
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vacciniforme-like lymphoma (Quintanilla-Martinez et al., 2008),
aggressive NK cell leukemia (Chan et al., 2008a), and chronic
active EBV disease (CAEBV) (Fox et al., 2011; Kimura et al., 2012,
2013). Some of these malignancies are refractory and resistant to
conventional chemotherapies, partly because of their expression
of P-glycoproteins (Suzuki et al., 2010). Thus, effective treatments
for T and NK cell lymphomas are needed, and novel approaches
involving targeted molecular therapies are desirable.
Infection with EBV has two possible outcomes. In a lytic infec-
tion, virions are produced and the host cell is lysed. Alterna-
tively, EBV can latently infect cells by generating an episome,
or circular EBV genome, in the nucleus of host lymphocytes.
Latent infections may be subdivided into three types based on
the pattern of EBV gene expression as follows: latency I: EBV
nuclear antigen 1 (EBNA1), EBV-encoded small RNA (EBER),
and BamHI-A rightward transcripts (BARTs); latency II: EBNA1,
EBER, BARTs, latent membrane protein 1 (LMP1), and LMP2;
and latency III: EBNA1, EBER, BARTs, LMP1, LMP2, EBNA2,
EBNA3, and EBNA-LP (Cohen, 2000).
LMP1 is a major oncoprotein that activates the nuclear
factor kappa B (NF-κB), c-Jun N-terminal kinase (JNK), and
phosphatidylinositol 3-kinase (PI3K) signaling pathways, thus
inhibiting apoptosis and promoting cell growth and prolifera-
tion (Damania, 2004). LMP1 is expressed in most EBV-positive
T and NK cell lymphomas because latency II is seen in these
EBV-infected cells (Kubota et al., 2008; Iwata et al., 2010).
We previously screened small-molecule inhibitors that
repressed LMP1 expression to explore potential targets for
the treatment of T and NK cell lymphomas (Murata et al.,
2013). Using EBV-positive cell lines and a library of small-
molecule inhibitors, we identified radicicol and 17-allyl-17-
demethoxygeldanamycin (17-AAG). Interestingly, both drugs
were heat shock protein 90 (Hsp90) inhibitors.
Hsp90 is a chaperone that functions in the correct folding of its
client proteins to their active conformation (Jhaveri et al., 2012).
Overexpression of Hsp90 is detected in various cancers, and
many of the client proteins of Hsp90 include oncoproteins with
important functions in the development and promotion of cancer
(Whitesell and Lindquist, 2005). Recently, someHsp90 inhibitors
have been evaluated in cancer (Jhaveri et al., 2012). We already
showed that radicicol and 17-AAG suppressed LMP1 expression
and cell proliferation in B, T, and NK cell lymphoma cell lines
(Murata et al., 2013). However, 17-AAG, a first-generation Hsp90
inhibitor, has limitations in clinical use because of drug insol-
ubility and hepatotoxicity, diarrhea, and fatigue (Jhaveri et al.,
2012).
BIIB021, a second-generation Hsp90 inhibitor, is a purine
scaffold-based Hsp90 inhibitor that binds to the ATP-binding
pocket of Hsp90 and interferes with Hsp90 chaperone function,
resulting in client protein degradation and tumor growth inhi-
bition (Lundgren et al., 2009; Jhaveri and Modi, 2012). Further-
more, BIIB021 can be administered orally. BIIB021 has antitumor
activity against Hodgkin lymphoma and Kaposi sarcoma-
associated herpes virus-associated primary effusion lymphoma
(Boll et al., 2009; Gopalakrishnan et al., 2013), and it has been
evaluated in a phase I clinical trial involving solid tumors (Saif
et al., 2014) and a phase II clinical trial involving gastrointestinal
stromal tumors (Dickson et al., 2013). In this study, we explored
the effects of the Hsp90 inhibitor BIIB021 in EBV-associated T
and NK lymphoma cell lines. Additionally, we investigated the
in vivo effects of BIIB021 in the NOD/Shi-scid/IL-2Rγnull (NOG)
mouse model.
Materials and Methods
Cell Lines and Reagents
SNT13 and SNT16 are EBV-positive T cell lines (Zhang et al.,
2003), and KAI3 (Tsuge et al., 1999) and SNK6 (Zhang et al.,
2003) are EBV-positive NK cell lines. Jurkat (Kaplan et al., 1976)
and KHYG1 (Yagita et al., 2000) are EBV-negative T and NK
cell lines, respectively. SNT13, SNT16, and KAI3 were derived
from patients with CAEBV, and SNK6 was derived from an
extranodal NK/T-cell lymphoma, nasal type.MT-2/rEBV/9-7 and
MT-2/rEBV/9-9 were established through the infection of MT-
2 cells with the hygromycin-resistant EBV strain B-95 (Miyoshi
et al., 1981; Fujiwara and Ono, 1995). MT-2/hyg/CL2 and MT-
2/hyg/CL3 cells were transfected with a hygromycin resistance
gene as controls. NKL was derived from a patient with large gran-
ular lymphocyte leukemia (Robertson et al., 1996), and the TL1
cell line was established from NKL cells infected with an Akata-
transfected recombinant EBV strain carrying a neomycin resis-
tance gene (Isobe et al., 2008). The characteristics of each cell line
are summarized in Table 1.
BIIB021 was purchased from LC Laboratories (Woburn, MA).
It was dissolved in dimethyl sulfoxide (DMSO).
Real-Time RT-PCR
Cells were treated with DMSO or 5µM BIIB021 for 24 and 48 h,
after which RNA was extracted using a QIAmp RNeasy Mini Kit
(Qiagen, Hilden, Germany). Viral mRNA expression was quanti-
fied by one-step multiplex real-time reverse transcription (RT)-
PCR using an Mx3000P real-time PCR system (Stratagene, La
Jolla, CA), as described previously (Kubota et al., 2008; Iwata
et al., 2010). The expression of viral mRNA was determined
TABLE 1 | Characteristics of the cell lines.
Cell type Cell line EBV Cell origin
T cell line SNT13 + CAEBV
SNT16 + CAEBV
Jurkat − Acute T lymphoblastic leukemia
MT-2/rEBV/9−7 + MT-2 cell line (adult T-cell leukemia)
MT-2/rEBV/9−9 + MT-2 cell line (adult T-cell leukemia)
MT-2/hyg/CL2 − MT-2 cell line (adult T-cell leukemia)
MT-2/hyg/CL3 − MT-2 cell line (adult T-cell leukemia)
NK cell line KAI3 + CAEBV
SNK6 + Extranodal NK/T cell lymphoma
KHYG1 − Aggressive NK cell leukemia
TL1 + NKL cell line
NKL − Large granular lymphocyte leukemia
EBV, Epstein-Barr virus; CAEBV, Chronic active Epstein-Barr virus disease.
Frontiers in Microbiology | www.frontiersin.org 2 April 2015 | Volume 6 | Article 280
Suzuki et al. BIIB021 suppresses T/NK cell lymphomas
in comparison with β2-microglobulin mRNA as an endogenous
control. Each experiment was conducted in duplicate; the results
are shown as the mean of two samples.
Western Blotting
After treatment with DMSO or 5µM BIIB021 for 24 and
48 h, whole-cell extracts were lysed directly with sodium dode-
cyl sulfate (SDS) sample buffer (50mM Tris-HCl, pH 6.8, 2%
sodium dodecyl sulfate, 10% glycerol, 6% 2-mercaptoethanol,
and 0.0025% bromophenol blue), briefly sonicated, and sepa-
rated by SDS polyacrylamide gel electrophoresis (SDS-PAGE).
The primary antibodies used were as follows: anti-LMP1 (S12)
at 1:50, anti-EBNA1 (provided by Teru Kanda, Aichi Can-
cer Center, Aichi, Japan) at 1:1000, anti-β-actin (#A5316;
Sigma, St. Louis, MO) at 1:5000, anti-phospho-Akt (#4058;
Cell Signaling Technology, Danvers, MA) at 1:1000, anti-Akt
FIGURE 1 | BIIB021 decreased the expression of latent membrane
protein 1 (LMP1) and Epstein-Barr virus (EBV) nuclear antigen 1
(EBNA1). (A) EBV-positive T cell lines (SNT13 and SNT16) and
EBV-positive NK cell lines (KAI3 and SNK6) were treated with DMSO or
5µM BIIB021 and harvested after 0, 24, and 48 h to evaluate
EBV-encoded gene expression using real-time RT-PCR. β2-Microglobulin
was used as an endogenous control and reference gene for relative
quantification and assigned an arbitrary value of 1 (10◦). All data are
expressed as means ± SEM. (B) Cells were treated with DMSO or 5µM
BIIB021 for 24 or 48 h. Cell lysates were collected and immunoblotting
was performed using anti-LMP1 and -EBNA1 antibodies. β-Actin was
used as a loading control.
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(#9272; Cell Signaling Technology) at 1:1000, anti-NF-κB (p65)
(#610868; BD Biosciences, Franklin Lakes, NJ) at 1:250, anti-IκBα
(#4814; Cell Signaling Technology) at 1:1000, anti-poly(ADP-
ribose) polymerase (PARP) (P248; Sigma) at 1:1000, anti-CDK1
(#612306; BD Biosciences) at 1:250, anti-CDK2 (#610145; BD
Biosciences) at 1:2500, anti-cyclin D3 (#610279; BD Biosciences)
at 1:1000, anti-JNK (#9258; Cell Signaling Technology) at
1:1000, anti-phospho-JNK (#4668; Cell Signaling Technology),
anti-janus kinase 3 (JAK3) (#3775; Cell Signaling Technology)
at 1:1000, anti-signal transducer and activator of transcription
(STAT) 3 (#4904; Cell Signaling Technology) at 1:1000, anti-
phospho-STAT3 (#9145; Cell Signaling Technology) at 1:1000,
anti-STAT5 (#9363; Cell Signaling Technology) at 1:1000, and
anti-phospho-STAT5 (#4322; Cell Signaling Technology) at
FIGURE 2 | BIIB021 decreased the viability of EBV-positive
and -negative T and NK cells and showed no adverse effects
on human PBMCs. (A) EBV-positive (SNT13 and SNT16)
and -negative (Jurkat) T cell lines, (B) EBV-positive (KAI3 and SNK6)
and -negative (KHYG1) NK cell lines, (C) EBV-positive T cell lines
(MT2/rEBV/9-7 and MT2/rEBV/9-9) and EBV-negative T cell lines
(MT2/hyg/CL2 and MT2/hyg/CL3), (D) an EBV-positive NK cell line
(TL1), and an EBV-negative NK cell line (NKL) were used. Each cell
line was cultured with DMSO or various concentrations of BIIB021.
Viability was calculated as the percentage of viable cells among
BIIB021-treated cells vs. DMSO-treated cells. Each cell line was
cultured with 5µM BIIB021 for the indicated times (left) or with the
indicated concentrations of BIIB021 for 96 h (right). The filled markers
represent EBV-positive cell lines and the open markers represent
EBV-negative cell lines. (E) Human PMBCs, isolated from three healthy
volunteers, were cultured with DMSO or 5µM BIIB021 for 96 h.
Viability was calculated as the percentage of viable cells among
BIIB021-treated cells vs. DMSO-treated cells. Bars indicate SEMs.
Frontiers in Microbiology | www.frontiersin.org 4 April 2015 | Volume 6 | Article 280
Suzuki et al. BIIB021 suppresses T/NK cell lymphomas
1:1000. The secondary antibodies used were goat anti-mouse
IgG-HRP conjugate (AMI3404; BioSource International, Camar-
illo, CA) and HRP-goat anti-rabbit IgG (H+L) (656120; Invitro-
gen, Carlsbad, CA). The bands were visualized using aWEST-one
Western Blot Detection System (iNtRON Biotechnology, Seong-
nam, Korea) or Chemi-Lumi One Super (Nacalai Tesque, Kyoto,
Japan). To compare the amount of each protein, densitomet-
ric analysis was performed using ImageJ software version 1.46r
(NIH, Bethesda, MD).
Cell Viability Assay
Cells (2 × 105/mL) were cultured in 24-well plates for 96 h with
DMSO or various concentrations of BIIB021, and cell viability
was quantified by trypan blue exclusion. Human peripheral blood
mononuclear cells (PBMCs) were isolated from healthy donors
using Ficoll-Paque gradient centrifugation and cultured in 24-
well plates for 96 h with 5µM BIIB021 or DMSO. These exper-
iments were performed in triplicate; the results shown are the
mean of three wells.
Flow Cytometric Apoptosis Assay
Cells (2 × 105/mL) were cultured in 24-well plates for
48 h with DMSO or 5µM BIIB021, and apoptosis was
measured by flow cytometry using an annexin V-phycoerythrin
(PE)/7-aminoactinomycin D (7-AAD) apoptosis assay kit (BD
Pharmingen Biosciences, San Diego, CA) according to the manu-
facturer’s protocol. Stained cells were analyzed using a FACSCal-
ibur (BectonDickinson, San Jose, CA) flow cytometer and FlowJo
(Tree Star, Ashland, OR) software.
Cell Cycle Assay
Cells (2 × 105/mL) were cultured in 24-well plates for 48 h
with DMSO or 5µM BIIB021, fixed with 70% ethanol, and then
washed with ice-cold PBS. The fixed cells were treated with
DNase-free RNase and stained with propidium iodide (Sigma).
The stained cells were analyzed with a FACSCalibur flow cytome-
ter and ModFit LT software (Verity Software House, Topsham,
ME). These experiments were performed in triplicate; the results
shown are the mean of three wells.
Animal Studies
Female NOG mice were purchased from the Central Institute
for Experimental Animals, Kawasaki, Japan. SNK6 cells (1× 106
cells) were injected subcutaneously into the right flank of the six
mice on day 0, as described previously (Siddiquey et al., 2014).
DMSO or BIIB021 (120mg/kg) was administered orally to three
mice each three times per week, from day 4 to day 30. The
FIGURE 3 | BIIB021 induced apoptosis in some EBV-positive
and -negative T and NK cell lines. EBV-positive T cell lines
(SNT13 and SNT16), an EBV-negative T cell line (Jurkat),
EBV-positive NK cell lines (KAI3 and SNK6), and an EBV-negative
NK cell line (KHYG1) were cultured with DMSO or 5µM BIIB021
for 48 h. Apoptosis was measured by flow cytometry after annexin
V-phycoerythrin (annexin V) and 7-aminoactinomycin D (7-AAD)
staining.
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dimensions of the tumors were measured using calipers twice per
week and calculated using the formula: pi × short axis × long
axis × height/6. The student’s t-test was used to compare tumor
volumes. All animal experiments were approved by the Univer-
sity Committee in accordance with the Guidelines for Animal
Experimentation at Nagoya University (Nagoya, Japan).
Results
BIIB021 Decreases LMP1 Gene and Protein
Expression in EBV-Positive T and NK Cell Lines
First, we examined the effects of BIIB021 on LMP1 gene and pro-
tein expression in EBV-positive cell lines. Figure 1A shows the
quantification of EBV mRNA expression by real-time RT-PCR.
BIIB021 decreased LMP1 gene expression in all EBV-positive
cell lines. Next, we confirmed the expression of LMP1 protein
by Western blotting (Figure 1B and Supplementary Table 1).
Although the expression levels of LMP1 differed among cell lines,
probably due to the difference of regulation of LMP1 in each cell
line, BIIB021 decreased the expression of LMP1. We also exam-
ined the expression of other EBV-encoded latent and lytic genes
(Figure 1A). BIIB021 decreased EBNA1 gene expression in all
EBV-positive cell lines and decreased EBNA1 protein expression
in some cell lines (Figure 1B and Supplementary Table 1). How-
ever, BIIB021 did not affect the expression of other latent genes,
although it slightly decreased BZLF1 mRNA in some cell lines
(Figure 1A).
BIIB021 Decreased the Viability of T and NK Cell
Lines
We next evaluated the effects of BIIB021 on the viability of T and
NK cell lines (Figure 2). EBV-positive T cell lines (SNT13 and
SNT16) and NK cell lines (KAI3 and SNK6) were cultured with
various concentrations of BIIB021. BIIB021 decreased the viabil-
ity of the EBV-positive T and NK cell lines in a time- and dose-
dependent manner. In comparison, when the EBV-negative T cell
line (Jurkat) and NK cell line (KHYG1) were cultured under the
same conditions, BIIB021 decreased their viability. Indeed, we
found no significant differences between the EBV-positive and -
negative cell lines (Figures 2A,B). To directly compare the effects
of BIIB021 on EBV-positive and -negative cells, we administered
BIIB021 to EBV-infected MT2 cell lines and their controls (T cell
lines, Figure 2C), TL1 and parental NKL cells (NK cell lines,
Figure 2D). We found no difference in the effects of BIIB021 on
these cell lines. Moreover, we administered BIIB021 to human
PBMCs to evaluate any adverse effects. More than 80% of the cells
were viable after 96 h (Figure 2E), indicating modest toxicity.
FIGURE 4 | BIIB021 decreased apoptosis- and cell
growth-related protein expression in EBV-positive and -negative
cell lines. EBV-positive T cell lines (SNT13 and SNT16), an
EBV-negative T cell line (Jurkat), EBV-positive NK cell lines (KAI3
and SNK6), and an EBV-negative NK cell line (KHYG1) were
cultured with DMSO or 5µM BIIB021 for 24 or 48 h. Whole cell
lysates were collected and subjected to immunoblotting using
anti-poly(ADP-ribose) polymerase (PARP), -nuclear factor kappa B
(NF-κB), -Iκ-Bα, -c-Jun N-terminal kinase (JNK), -phospho-JNK,
-Akt, -phospho Akt, -Janus kinase 3 (JAK3), -signal transducer and
activator of transcription (STAT) 3, -phospho-STAT3, -STAT5,
phospho-STAT5, and -β-actin antibodies.
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BIIB021 Induces Apoptosis in T and NK Cell Lines
Next, we analyzed the induction of apoptosis by flow cytome-
try with annexin V and 7-AAD staining. BIIB021 increased early
apoptotic cells, defined as those positive for annexin V and nega-
tive for 7-AAD staining, in the two T cell lines, SNT16 and Jurkat,
and two NK cell lines, SNK6 and KHYG1 (Figure 3). We then
investigated the levels of PARP and cleaved PARP by Western
blotting. BIIB021 induced cleaved PARP in all cell lines, indicat-
ing that the drug induced apoptosis in these cells (Figure 4 and
Supplementary Table 2).
BIIB021 Decreases LMP1 Downstream Signaling
Pathways in T and NK Cell Lines
The NF-κB, JNK, and PI3K signaling pathways are downstream
of LMP1 (Young and Rickinson, 2004). Thus, we examined
the expression of these proteins (Figure 4 and Supplementary
Table 2). BIIB021 decreased NF-κB, JNK, phospho-JNK, Akt,
and phospho-Akt expression, although the extent of the decrease
differed among the cell lines. However, BIIB021 also decreased
the expression of these proteins in EBV-negative cells. We also
examined the JAK/STAT pathway that is presumably upstream of
LMP1. BIIB021 decreased JAK3, phospho-STAT3, and phospho-
STAT5, indicating that the drug inhibits the JAK/STAT pathway
(Figure 4 and Supplementary Tables 2, 3).
BIIB021 Induces a Cell Cycle Arrest in T Cell and
NK Cell Lines
To determine the mechanism of the growth inhibition induced
by BIIB021, we investigated the effects of BIIB021 on the
cell cycle using flow cytometry with propidium iodide stain-
ing (Figure 5A). The population of cells in both G1 and G2
increased in all T cell lines following exposure to BIIB021, while
the population in G1 phase increased in the NK cell lines. Several
cell cycle-related proteins were investigated by Western blotting
(Figure 5B and Supplementary Table 4). CDK1, which is associ-
ated with the G2/M checkpoint, and CDK2 and cyclin D3, which
are associated with the G1 checkpoint, were decreased by BIIB021
in all of the cell lines tested.
BIIB021 Inhibits EBV-Positive NK Cell Lymphoma
Growth in a Murine Xenograft Model
Finally, we investigated the effect of BIIB021 using an NOG
mouse xenograft model (Figure 6). NOG mice are completely
immunodeficient and can accept the EBV-positive NK cell line
SNK6 (Siddiquey et al., 2014). When we inoculated SNK6 cells
subcutaneously, tumors developed rapidly. After the subcuta-
neous inoculation of SNK6, we administered BIIB021 orally and
measured the tumor volumes. BIIB021 inhibited the growth of
EBV-positive NK cell lymphomas compared with the results in
control mice (p < 0.05).
FIGURE 5 | BIIB021 induced a cell cycle arrest in EBV-positive
and -negative cell lines. (A) EBV-positive T cell lines (SNT13 and SNT16),
an EBV-negative T cell line (Jurkat), EBV-positive NK cell lines (KAI3 and
SNK6), and an EBV-negative NK cell line (KHYG1) were cultured with DMSO
or 5µM BIIB021 for 48 h. Cell cycle status was measured by flow cytometry
using propidium iodide staining. (B) Cells were cultured with DMSO or 5µM
BIIB021 for 24 or 48 h. Whole cell lysates were collected and subjected to
immunoblotting using anti-CDK1, -CDK2, -cyclin D3, and -β-actin antibodies.
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FIGURE 6 | BIIB021 inhibited the growth of EBV-positive NK cell
lymphomas in a murine xenograft model. NOD/Shi-scid/IL-2Rγnull (NOG)
mice were implanted subcutaneously with 1× 106 SNK6 (EBV-positive NK)
cells on the right flank. From days 4 to 30, DMSO (vehicle) or BIIB021
(120mg/kg) was administered orally three times per week. The tumor volume
was measured twice per week. Bars indicate the SEM. *p < 0.05.
Discussion
EBV-associated T and NK cell lymphomas are refractory and
resistant to chemotherapy; thus, new treatment agents are nec-
essary. We have shown the antitumor activities of several drugs
against EBV-associated T and NK cell lymphomas (Iwata et al.,
2011, 2012; Kanazawa et al., 2014; Kawada et al., 2014; Siddiquey
et al., 2014). In the present study, we focused on the major
oncogene LMP1, and found that the Hsp90 inhibitor BIIB021
decreased LMP1 gene expression and inhibited cell prolifera-
tion. The mechanism underlying the down-regulation of LMP1
by BIIB021 is, however, unclear.
The regulation of LMP1 expression differs between latency II
and III. LMP1 transcription is regulated by EBNA2 in latency
III (Laux et al., 1994; Johannsen et al., 1995), whereas in latency
II, where EBV-infected T or NK cells belong, LMP1 expression
is regulated by the JAK/STAT pathway, which is stimulated by
cytokines, including IL-4, IL-6, IL-10, IL-13, and IL-21 (Chen
et al., 2001, 2003; Kis et al., 2006, 2010, 2011). JAK/STAT signal-
ing can be inhibited by Hsp90 inhibitors (Schoof et al., 2009).
Because EBV-positive T and NK cell lines are dependent on
IL-2 and LMP1 is upregulated by IL-2 (Takahara et al., 2006),
Hsp90 inhibitors may suppress LMP1 expression by blocking the
JAK/STAT pathway activated by IL-2 (Murata et al., 2013). In
the present study, the JAK/STAT pathway was actually down-
regulated byBIIB021.Moreover, JNK andNF-κB signaling, which
was down-regulated by BIIB021 in this study, regulates LMP1
expression (Goormachtigh et al., 2006). BIIB021 may decrease
LMP1 expression in EBV-positive T and NK cell lines in type
II latency by down-regulating more than one pathway. How-
ever, Sun et al. reported that Hsp90 inhibitors increased LMP1
expression in type III latency B cell lines (Sun et al., 2010). Thus,
different regulatory mechanisms of LMP1 expression may exist
between type II and type III latency cells.
We suggest that BIIB021 inhibited the function of proteins
upstream of LMP1, leading to the down-regulation of LMP1 and
inhibition of cell growth. To clarify the role of LMP1 in the
inhibitory effect of BIIB021, we attempted to silence LMP1 using
siRNA in Hsp90 inhibitor-treated cells. However, because of poor
induction efficiency in the EBV-positive T and NK cell lines,
we have not yet succeeded. Re-induction of LMP1 in BIIB021-
treated T or NK cell lines was also tried, but it was so stress-
ful to the cell lines that we could not evaluate their cell growth
and viability. We have established EBV-negative T cell lines that
express LMP1 inducibly using the Tet-on system (Ito et al., 2014);
however, LMP1 alone was not sufficient to enhance the prolif-
eration of these cell lines, so they could not be used to evaluate
the effect of Hsp90 inhibitors. In this study, BIIB021 also sup-
pressed the proliferation of EBV-negative cell lines. More than
200 proteins have been reported to be Hsp90 clients (Hong et al.,
2013). BIIB021 presumably inhibits the functions of many Hsp90
substrates in EBV-positive and -negative T and NK cell lines,
resulting in cell growth inhibition, cell cycle arrest, and apop-
tosis induction. Of these mechanism, cell cycle arrest is partic-
ularly important, since BIIB021 induced the cell cycle arrest in
all cell lines. Both CDK1 and CDK2 are known to be client pro-
teins for HSP90 (Prince et al., 2005; Wang et al., 2011). They are
protein kinases that regulates cell cycle progression through the
association with cyclins. Activated CDK1 and CDK2 are able to
phosphorylate downstream effector proteins and drive G2/M and
S/G2 transitions, respectively (Malumbres and Barbacid, 2009).
In this study, CDK1 and CDK2 were decreased by BIIB021 and
the cell cycle was arrested at either G1 or G2 phase. Thus, BIIB021
inhibits the functions of key proteins in cell cycle and thereby
causes cell growth inhibition.
BIIB021 decreased not only LMP1 but also EBNA1 expres-
sion. Sun et al. reported that Hsp90 inhibitors decreased EBNA1
expression in a latency III B cell line (Sun et al., 2010). EBNA1,
which is expressed on virtually all EBV-infected cells, acts in
the maintenance of the episomal EBV genome in host cells and
interacts with certain viral promoters (Young and Rickinson,
2004). Additionally, EBNA1 may contribute to tumorigenesis by
inhibiting apoptosis (Kennedy et al., 2003; Saridakis et al., 2005).
The down-regulation of EBNA1 may also be associated with the
suppression of cell growth in EBV-positive T and NK cells. Fur-
thermore, given that EBNA1 is required for maintaining EBV
episome in infected cells, EBNA1 down-regulation might lead to
a loss of EBV genome, resulting in “cure” of lymphoma cells.
When we applied BIIB021 to human PBMCs, the viability
of the treated cells remained high, indicating the absence of
major toxic effects. Moreover, we did not observe any significant
adverse events, such as body weight loss or death, in the mouse
study. A phase II clinical trial of BIIB021 for gastrointestinal
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stromal tumors has been performed (Dickson et al., 2013). Some
adverse events were observed, including nausea, vomiting, diar-
rhea, and hepatotoxicity; however, these effects were generally
mild to moderate, so we believe that BIIB021 is likely acceptable
for clinical use. Furthermore, while resistance toHsp90 inhibitors
has not been reported in clinical trials or in vitro experiments,
drug resistance may occur with long-term use. Additionally, the
effects of Hsp90 inhibitors are generally modest and are not
effective enough to induce complete remission. Thus, we need
combined therapies with chemotherapeutic agents or other tar-
geted molecular therapies for the treatment of T and NK cell
lymphomas.
In this paper, we showed that BIIB021 decreased LMP1 and
EBNA1mRNA and protein expression in EBV-positive T andNK
cell lines. In addition, we showed that BIIB021 treatment induced
apoptosis, arrested the cell cycle, and suppressed the prolifera-
tion of EBV-positive and -negative T and NK cell lines. BIIB021
also inhibited the growth of EBV-positive NK cell lymphomas in
a murine xenograft model. These results suggest that BIIB021 has
potential as a new treatment for EBV-associated T and NK cell
lymphomas, although its effect may be independent of EBV.
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